Old Web
English
Sign In
Acemap
>
authorDetail
>
Caleb A. Bliss
Caleb A. Bliss
Merck & Co.
Levofloxacin
Population
Tazobactam
Ceftolozane
Microbiology
3
Papers
120
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
2017
Journal of Antimicrobial Chemotherapy
Myra W. Popejoy
David L. Paterson
Daniel J. Cloutier
Jennifer A. Huntington
Benjamin Miller
Caleb A. Bliss
Judith N. Steenbergen
Ellie Hershberger
Obiamiwe Umeh
Keith S. Kaye
Show All
Source
Cite
Save
Citations (79)
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial
2016
Journal of Antimicrobial Chemotherapy
Jennifer A. Huntington
George Sakoulas
Obiamiwe Umeh
Daniel J. Cloutier
Judith N. Steenbergen
Caleb A. Bliss
Ellie J. C. Goldstein
Show All
Source
Cite
Save
Citations (37)
Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections
2016
BMC Infectious Diseases
Eliana S. Armstrong
Janelle A. Mikulca
Daniel J. Cloutier
Caleb A. Bliss
Judith N. Steenbergen
Show All
Source
Cite
Save
Citations (4)
1